0.57
-0.86%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Pharma Holdings
From its filings with the US Securities and Exchange Commission
China Pharma Holdings is based in Hainan Province, China and is incorporated in Delaware. Its shares trade on NYSE under the ticker CPHI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $4.1m and a net loss of $3.2m. At that date it held total assets of $31.0m and shareholders' equity of $22.7m.
Modern Traditional Chinese Medicines (“TCMs”), which are generally comprised of non-synthetic, plant-based medicinal compounds that have been widely used in the PRC for thousands of years. We apply modern production techniques to produce pharmaceutical products in different formulations, such as tablets, capsules or powders.
Guidelines limit applications for identical products to three years post-initial approval, fostering innovation.
(Supplier-to-Business-to-Consumer) model, supported by digital tools, will enhance sales performance and market accessibility.
Memory decline and attention deficit disorder caused by the sequela of craniocerebral trauma and cerebrovascular diseases.
Tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain, including vertigo, neuralgia and headaches.
Cerebral thrombosis, coronary heart disease and complications after surgery such as thrombus deep phlebitis.
Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.
Various edema diseases (including those associated with heart failure, hepatic cirrhosis, nephropathy, and pulmonary edema), hypertension, acute renal failure, hyperkalemia, hypercalcemia and for the rescue from acute drug poisoning.
Quoted from its 10-K, filed 1 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Feb 2000
- Employees
- 221
- Website
- chinapharmaholdings.com ↗
- Head office
- 2ND FLOOR, NO. 17, JINPAN ROAD, HAINAN PROVINCE, F4, 570216
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Zhilin LiChairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, since 2005$241,600
- Ms. Heung TsuiDirector$16,000
- Mr. Gene BennettIndependent Director$16,000
- Mr. Baowen DongIndependent Director$5,799
- Yingwen ZhangIndependent Director$5,799
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Pharma Holdings employs 228 full-time employees in Haikou, Hainan.
- The company manufactures over 20 pharmaceutical products approved by the CFDA.
- Hainan Helpson Medical & Biotechnology Co., Ltd. handles production and marketing activities.
Weaknesses
- The company's headquarters city is Haikou, Hainan, which is not a major pharmaceutical hub.
- China Pharma Holdings has no international presence beyond the PRC.
- The firm's product range focuses solely on the Chinese market.
Opportunities
- The PRC pharmaceutical market continues to grow steadily for CNS and Cerebral-Cardiovascular Diseases.
- Hainan Helpson Medical & Biotechnology Co., Ltd. could expand its product portfolio in Anti-infection and Respiratory Diseases.
- China's healthcare reforms may increase demand for pharmaceutical products.
Threats
- The CFDA approval process could delay new product launches significantly.
- China's strict pharmaceutical regulations may increase production costs.
- The PRC market is highly competitive with many domestic pharmaceutical companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.